Chronic Lymphocytic Leukemia Clinical Trial
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Summary
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
Eligibility Criteria
Inclusion Criteria:
Patients with a diagnosis that qualifies them for a DUCBT
Absence of recent active mold infection
Adequate organ function
Availability of eligible donor material
Exclusion Criteria:
Pregnancy or breastfeeding women and women of child-bearing potential unless two acceptable forms of contraception are being used
Human immunodeficiency virus (HIV) infection
Active infection
Extensive prior chemotherapy
Prior myeloablative allotransplantation or autologous transplant.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Minneapolis Minnesota, 55455, United States
How clear is this clinincal trial information?